Products
Antisoma focuses its activities on treatments for cancer, an area of significant unmet medical need.
Antisoma has a diverse portfolio of products in development. Our products target tumours by several different mechanisms and are intended for the treatment of a range of cancers.
ASA404 (DMXAA, formerly AS1404)
A first-in-class Tumour-Vascular Disrupting Agent (Tumour-VDA) in trials for various solid tumours and entering phase III in non-small cell lung cancer.
More on ASA404AS1413 (amonafide malate, formerly XanafideŽ)
AS1413, formerly XanafideŽ, is a DNA intercalator in phase III development in secondary AML.
More on AS1413AS1411
A DNA aptamer in phase II in acute myeloid leukaemia (AML).
More on AS1411Oral fludarabine
Oral fludarabine is a nucleoside analogue in registration for CLL.
More on Oral fludarabineAS1402 (huHMFG1)
A humanised monoclonal antibody against MUC1 being prepared for a phase II trial in breast cancer.
More on AS1402AS1409 (huBC1-huIL12)
An antibody-cytokine fusion protein for targeted delivery of IL-12 currently in phase I in renal cell carcinoma and melanoma.
More on AS1409P2045
P2045 is a synthetic peptide-based targeted radiopharmaceutical in phase I studies.
